BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1913228)

  • 1. Evaluation of two consecutive regimens in advanced gastric cancer.
    Figoli F; Galligioni E; Crivellari D; Frustaci S; Talamini R; Sorio R; Saracchini S; Tumolo S; Lo Re G; Monfardini S
    Cancer Invest; 1991; 9(3):257-62. PubMed ID: 1913228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; RodinĂ² C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer.
    Wagener DJ; Yap SH; Wobbes T; Burghouts JT; van Dam FE; Hillen HF; Hoogendoorn GJ; Scheerder H; van der Vegt SG
    Cancer Chemother Pharmacol; 1985; 15(1):86-7. PubMed ID: 4039985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer].
    Ozeki H; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Ito Y; Imajo K; Shinagawa K
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):91-5. PubMed ID: 3122669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
    Tsavaris NB; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekois D; Tsetis A; Klonaris C
    Am J Clin Oncol; 1996 Oct; 19(5):517-21. PubMed ID: 8823483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM).
    Faedi M; Amadori M; Gentilini P; Ridolfi R; Ravaioli A; Amadori D; Biserni R; Bonaguri C
    Chemioterapia; 1986 Aug; 5(4):240-3. PubMed ID: 3769045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
    Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
    Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
    Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
    Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma.
    Arbuck SG; Silk Y; Douglass HO; Nava H; Rustum YM; Milliron S
    Cancer; 1990 Jun; 65(11):2442-5. PubMed ID: 2337858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
    Kikuyama S; Inada T; Miyakita M; Ogata Y
    Jpn J Clin Oncol; 1998 May; 28(5):314-7. PubMed ID: 9703858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
    Cocconi G; Bella M; Zironi S; Algeri R; Di Costanzo F; De Lisi V; Luppi G; Mazzocchi B; RodinĂ² C; Soldani M
    J Clin Oncol; 1994 Dec; 12(12):2687-93. PubMed ID: 7989945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer.
    Wagener DJ; van Hoesel QG; Yap SH; Hoogenraad WJ; Wobbes T; Strijk SP
    Cancer Chemother Pharmacol; 1989; 25(2):131-4. PubMed ID: 2598399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
    Haim N; Epelbaum R; Cohen Y; Robinson E
    Cancer; 1984 Nov; 54(9):1999-2002. PubMed ID: 6548173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FEP and FAP combination chemotherapy in advanced gastric cancer. Research Group for Gastric Cancer].
    Hayakawa M; Morise K; Oka Y; Suga S; Suzuki T; Kaneshiro K; Tsunekawa H; Hayashi N; Umemura K; Yoshida H
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3073-9. PubMed ID: 2847659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
    Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of FAM regimen in 38 patients with advanced gastric cancer.
    Ridolfi R; Casadei Giunchi D; Cortesi C; Maltoni M; Ravaioli A; Amadori D
    Tumori; 1984 Aug; 70(4):375-9. PubMed ID: 6548054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
    Lupera H; Droz JP; Piot G; Lapleige P; Fargeot P; Theodore C
    Oncology; 1989; 46(6):372-4. PubMed ID: 2587004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Etoposide, doxorubicin, cisplatin and 5-FU (EAP-F) therapy of advanced gastric cancer--its antitumor effect and evaluation of quality of life].
    Suda K; Kano Y; Inada T; Ogata Y
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1791-5. PubMed ID: 8379671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.
    Norum J; Angelsen V
    J Chemother; 1995 Oct; 7(5):455-9. PubMed ID: 8596132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.